A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma

PURPOSE: Ceritinib is an orally bioavailable, small-molecule inhibitor of anaplastic lympoma kinase (ALK), insulin-like growth factor 1 receptor (IGFR1), and focal adhesion kinase (FAK), which are highly expressed in glioblastoma and many brain metastases. Preclinical and clinical studies indicate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Shwetal, Fiorelli, Roberto, Bao, Xun, Pennington-Krygier, Chelsea, Derogatis, Alanna, Kim, Seongho, Yoo, Wonsuk, Li, Jing, Sanai, Nader
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306447/
https://www.ncbi.nlm.nih.gov/pubmed/34702773
http://dx.doi.org/10.1158/1078-0432.CCR-21-1096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306447/
https://www.ncbi.nlm.nih.gov/pubmed/34702773
http://dx.doi.org/10.1158/1078-0432.CCR-21-1096

Ejemplares similares